Department of Psychiatry, University of California, San Francisco, CA, USABrain & Mind Research Institute, University of Sydney, NSW, Australia.
Br J Pharmacol. 2012 Mar;165(6):1704-1716. doi: 10.1111/j.1476-5381.2011.01482.x.
Agonists acting on µ-opioid receptors (MOR) are very effective analgesics but cause tolerance during long-term or repeated exposure. Intensive efforts have been made to find novel opioid agonists that are efficacious analgesics but can elude the signalling events that cause tolerance. µ-Opioid agonists differentially couple to downstream signalling mechanisms. Some agonists, such as enkephalins, D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO), methadone and sufentanyl are efficacious at mediating G-protein and effector coupling, as well as triggering MOR regulatory events that include MOR phosphorylation, β-arrestin binding, receptor endocytosis and recycling. By contrast, morphine and closely related alkaloids can mediate efficacious MOR-effector coupling but poorly trigger receptor regulation. Several models have been proposed to relate differential MOR regulation by different opioids with their propensity to cause tolerance. Most are based on dogma that β-arrestin-2 (βarr-2) binding causes MOR desensitization and/or that MOR endocytosis and recycling are required for receptor resensitization. This review will examine some of these notions in light of recent evidence establishing that MOR dephosphorylation and resensitization do not require endocytosis. Recent evidence from opioid-treated animals also suggests that impaired MOR-effector coupling is driven, at least in part, by enhanced desensitization, as well as impaired resensitization that appears to be βarr-2 dependent. Better understanding of how chronic exposure to opioids alters receptor regulatory mechanisms may facilitate the development of effective analgesics that produce limited tolerance.
阿片受体(MOR)激动剂对μ-阿片受体(MOR)具有很强的镇痛作用,但在长期或反复暴露时会产生耐受。人们已经做出了巨大努力来寻找新的阿片类激动剂,这些激动剂是有效的镇痛药,但可以逃避导致耐受的信号事件。μ-阿片受体激动剂与下游信号机制有差异偶联。一些激动剂,如内啡肽、D-Ala(2)、N-Me-Phe(4)、Gly(5)-ol]-内啡肽(DAMGO)、美沙酮和舒芬太尼,在介导 G 蛋白和效应器偶联以及触发 MOR 调节事件方面非常有效,这些事件包括 MOR 磷酸化、β-arrestin 结合、受体内吞和再循环。相比之下,吗啡和密切相关的生物碱可以介导有效的 MOR-效应器偶联,但触发受体调节的能力很差。已经提出了几种模型来将不同阿片类药物对 MOR 的不同调节与它们引起耐受的倾向联系起来。大多数模型都是基于这样一种观点,即β-arrestin-2(βarr-2)结合导致 MOR 脱敏和/或 MOR 内吞和再循环是受体重新敏化所必需的。这篇综述将根据最近的证据,考察其中一些概念,这些证据表明 MOR 去磷酸化和再敏化不需要内吞作用。来自接受阿片类药物治疗的动物的最新证据还表明,MOR 效应器偶联的受损至少部分是由脱敏增强以及似乎依赖于βarr-2 的再敏化受损驱动的。更好地了解慢性暴露于阿片类药物如何改变受体调节机制,可能有助于开发产生有限耐受的有效镇痛药。